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Abstract Atypical Teratoid/Rhabdoid tumors (AT/RT)
of the central nervous system are rare but aggressive tumors
of childhood. Median survival with surgery and standard
chemotherapy is less than 12 months. In an attempt to
improve outcome, patients were treated with aggressive
surgical resection and multi-agent chemotherapy, followed
by high dose chemotherapy with autologous stem cell res-
cue. Nine consecutive children (median age 21 months)
were diagnosed with AT/RT at the University of California
San Francisco Childrens Hospital from 1997 to 2007 and
treated with this aggressive approach. Diagnosis was con-
firmed using molecular markers. There are two long-term
survivors (78 and 98 months from diagnosis). One addi-
tional patient is alive with disease. Three patients died of
disease during therapy. Three patients died of disease after
therapy was complete. There were no toxic deaths. Two of
nine patients treated for AT/RT at our institution with high
dose chemotherapy and autologous bone marrow transplant
are long-term survivors, suggesting that a subset of patients
can be cured with this approach.
Keywords CNS tumors 
Atypical teratoid/rhabdoid tumor  Autologous transplant
Introduction
Malignant rhabdoid tumors (MRT) are a rare group of
aggressive childhood tumors that most often arise in the
kidney. First described in 1978, these tumors have charac-
teristic large polygonal cells that contain globular, eosino-
philic cytoplasm and have vesicular nuclei, often with
prominent nucleoli [1]. These cells were reminiscent of
rhabdomyoblasts and so were called rhabdoid cells. Reports
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of primary intracranial tumors containing rhabdoid cells
exist as early as 1985 [2]. These heterogeneous tumors affect
young children and are composed of neuroepithelial,
peripheral epithelial, and mesenchymal elements (in addi-
tion to their characteristic rhabdoid cells) and were later
coined atypical teratoid/rhabdoid tumors (AT/RT) by Rorke
and others in 1995 [3]. Sections of these tumors can appear
identical to primitive neuro-ectodermal tumors (PNET’s) or
germ cell tumors on histology and therefore require immuno-
histochemical and cytogenetic data for definitive diagnosis.
Many of these tumors were classified under the generic
category of PNET in the past. However, the exact histo-
logic characterization is crucial as treatment outcomes may
differ. PNET/Medulloblastoma (MB)’s, for example, can
respond well to aggressive surgery and chemotherapy alone
[4]. AT/RT patients, on the other hand, have a very poor
prognosis when treated on PNET-MB protocols [5] and
respond only marginally better when treated with more
aggressive therapy. To date, approximately 200 cases of
AT/RT have been reported in the literature.
In this publication, we report on nine children identified
at our institution. All patients had their INI1 status exam-
ined at the protein or gene level and only those patients
found to be altered were included for further analysis.
Histological and molecular features as well as treatment
outcome are reported.
Methods
Inclusion criteria
All patients with newly diagnosed with central nervous sys-
tem AT/RT between May 1997 and January 2007 at the
University of California San Francisco (UCSF) are described.
Patient characteristics are shown in Table 1. This study was
approved by our institutional Committee on Human Research.
The diagnosis of CNS AT/RT was re-confirmed by one
of the authors (T.T) for all patients. The pathological
findings are presented in Table 2 and include molecular
diagnostics (immunohistochemistry for BAF47 or muta-
tional analysis for INI1) for all patients. BAF47 immuno-
histochemistry was performed using the BAF47/SNF5
mouse monoclonal antibody (BD Transduction Labs, San
Diego, CA) and INI1 mutation analysis was performed as
previously described [6]. Representative histology and
immunohistochemistry are shown in Fig. 1.
Results
Clinical features are presented in Table 1. All patients
presented with signs of increased intracranial pressure. Of
our nine patients, seven were male, which is in agreement
with the 2:1 male:female ratio reported by the ATRT
Registry [7]. The median age of diagnosis was 21 months
(range 6–49 months). Four out of nine tumors arose in a
twin. The tumors arose from throughout the neuraxis, and
disseminated disease was common. Six out of the nine
patients underwent a gross total resection (GTR), while
three had either a subtotal resection (STR) or a biopsy.
Adjuvant chemotherapy regimens included cisplatin,
vincristine, cyclophosphamide, and etoposide (used in
Childrens Cancer Group study 99703) or high-dose meth-
otrexate, cisplatin, vincristine, cytoxan, and etoposide
(used in the HeadStart-II study) [8]. Only one patient
received radiation therapy (Patient 2 received 64 Gray
conformal radiation prior to transplant).
Six patients achieved or sustained a complete response
(CR) with induction chemotherapy, while three patients
progressed during induction chemotherapy. Patients that
achieved a CR then went onto high dose chemotherapy
with autologous stem cell transplant (ASCT). Transplant
characteristics are described in Table 1. Transplants were
well tolerated and all patients engrafted within 16 days.
Follow-up duration ranged from 6 to 98 months. Median
Progression-Free Survival (PFS) as well as overall survival
(OS) was 10 months (range 1–98 months) (Fig. 2). There
were two long term survivors (PFS of 98 and 78 months).
Both of these patients underwent ASCT.
Discussion
Since being recognized as an independent entity, it has
become clear that patients with AT/RT have a dismal
prognosis. The original series described a median survival
of 6 months [3]. Subsequent treatment strategies have
consisted of intensive multi-modal therapy with surgery,
chemotherapy and/or radiation therapy. Because of the
rarity of the disease, clinical reports of patients with
AT/RT have been mostly anecdotal.
In this paper, we describe the series of patients treated
for AT/RT at our institution. As with other malignant
pediatric brain tumors, gross total resection (GTR) seemed
to be associated with better outcome in our series, with
both long-term survivors having had GTR’s, though the
small numbers precluded statistical evaluation (Fig. 2).
This is in agreement with the largest reported study of AT/
RT patients thus far, based on the multi-center national
registry. Retrospective data compiled on the AT/RT reg-
istry [7] reported OS of 20 months in 20 patients with GTR
versus 15 months in 22 patients with sub-total resection or
biopsy. Additionally, a recent report from Chi et al. [9]
demonstrated the importance of GTR in a prospective
multi-center trial. In that study, both overall survival and
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progression free survival were significantly higher in the
group of patients that underwent GTR. Unfortunately, GTR
is often not possible due to disseminated disease at diag-
nosis or disease located adjacent to vital structures. Adju-
vant therapy is required to cure patients with AT/RT, but
identifying the best therapy has proven difficult.
The role for radiation therapy is controversial in this
disease (reviewed in [10]). Although the incorporation of
external beam radiation therapy has resulted in some long
term survivors in children greater than 3 years of age [11],
most clinicians are hesitant to irradiate ‘‘infants’’ or chil-
dren younger than 3 years of age due to the significant risk
of neuro-endocrine toxicity (reviewed in [12]). In order to
avoid irradiation (or at least delay it until after 3 years of
age), clinicians have used high dose chemotherapy with
autologous stem cell transplantation (HD-ASCT). This
approach has increased survival in young children with
recurrent MB’s and supratentorial PNET’s [13, 14].
Adjuvant chemotherapy used to treat AT/RT’s is
aggressive and published series in the literature have used
one of two chemotherapeutic backbones: Intergroup
Rhabdomyosarcoma III (IRS-III) and Children’s Cancer
Group (CCG)-9921. Weinblatt and Kochen [15] first
reported the successful use of surgery, radiation therapy,
and combination chemotherapy using the IRS-III regimen
36 (originally designed to treat parameningeal rhabdomyo-
sarcoma) to treat a child with AT/RT. This chemotherapeutic
regimen consists of vincristine, cisplatin, doxorubicin,
cyclophosphamide, dacarbazine (replaced by the related
drug temozolomide in modern protocol), etoposide, actino-
mycin-D and triple intrathecal therapy with methotrexate,
hydrocortisone, and cytarabine. Olsen et al. [16] reported
Table 2 Pathological characteristics
Patient Rhabdoid cells EMA Vimentin S100 GFAP Synaptophysin BAF47 Nuclear staining Mutation analysis
1 ? ? ? - ± - Absent ?
2 ? ? ? - - ?
3 ? ? ? ? ? ?
4 ? ? ? ? - ? Absent ?
5 ? - ? - Absent ?
6 ? - ? - - Absent Not Done
7 ? ? ? ? - ? Absent Not Done
8 ? ? ? ? Absent Not Done
9 ? - ? - - ? Absent Not Done
Fig. 1 Immuno-histochemistry. a H and E of small cell component of
AT/RT. b H and E of large cell component, with necrotic area (arrow).
c Higher magnification of b. d Positive EMA stain. e Positive
Cytokeratin stain. f BAF47/INI1 antibody stain showing loss of INI1
expression in AT/RT. Retained expression is noted in scattered
inflammatory cells, constituting a positive internal control
120 J Neurooncol (2010) 98:117–123
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on an additional two long term survivors using this approach,
while Zimmerman et al. [17] successfully treated four con-
secutive patients using this approach. Of particular note,
two of the patients from the latter report were relapsed
patients who had failed conventional therapy. This regimen
can clearly be effective, but the requirement for radiation
therapy (focal stereotactic radiation therapy in ‘‘infants’’)
is controversial. One of the three ‘‘infants’’ treated by
Zimmerman et al. is reported to have significant cognitive
delay. During the preparation of this manuscript, the results
of a prospective multi-center trial using aggressive surgery,
IRS-III based induction chemotherapy (including intrathecal
chemotherapy) and radiation therapy to all patients
(including patients under 3 years of age) was published. Chi
et al. [9] reported 2-year progression-free and overall sur-
vival rates of 53 and 70%, respectively, in a cohort of 20
patients. This report is extremely encouraging and there will
be much interest in the long-term outcome of this cohort.
CCG-9921 (Regimen A) based therapy uses a four drug
induction regimen (vincristine, cisplatin, cyclophospha-
mide, etoposide) found to be the most active arm against
embryonal tumors [18]. This backbone has been used as the
induction regimen for the ‘‘Headstart’’ protocols and for
CCG-99703 which add HD-ASCT in place of radiation
therapy in order to further intensify therapy in ‘‘infants’’. A
recent report by Gardner et al. [8] described the outcomes
of AT/RT patients treated with the Headstart protocols. The
prospective study spanned 10 years and two versions of the
protocol, with ‘‘Headstart II’’ adding high dose metho-
trexate to the regimen. Myeloablative chemotherapy prior
to transplant consisted of carboplatin, thiotepa and etopo-
side. While high dose methotrexate has activity against
embryonal brain tumors [19], it also significantly adds to
the rate of toxic deaths. The prospective report from
Gardner et al. describes thirteen patients treated on Head-
start I and II and reports three long term survivors. Two out
of three of these patients received induction with high dose
methotrexate. Also, most patients in Gardner’s study did
not have confirmation with INI1 analysis, as they were
treated before the test became available. However,
the three long term survivors have had their diagnosis
confirmed by INI1 analysis (S.L. Gardner, personal
communication).
Our study reports on nine consecutive patients treated at
a single institution for AT/RT. Induction chemotherapy
varied in our series. Four patients were treated per Head-
start II, but only one of these patients was treated on study.
That patient (#4 in our study) is a long term survivor and
was previously reported (as patient HSII #6) in the recent
report by Gardner et al. [8]. Two patients were treated per
CCG-99703 and the others varied. Although induction
chemotherapy varied in our series, all patients were treated
with intensive chemotherapy and then taken to HD-ASCT
if they were in CR. Myeloablative chemotherapy consisted
of one cycle for four patients, and of three smaller trans-
plants for the two patients on CCG-99703. Our patients
tolerated therapy well with no toxic deaths. Of the six
patients that underwent HD-ASCT, three remain alive at
the time of this report, with two of these patients being long
term survivors ([5 years survival).
All patients in our study had their diagnosis confirmed
with the histological presence of rhabdoid cells, immuno-
histochemical evidence of epithelial and/or mesenchymal
markers and the inactivation of INI1—defined by either
INI1 mutation/deletion or loss of nuclear expression of
BAF47. Confirmation of an AT/RT diagnosis is critical as
clinical trials are being designed for AT/RT. In a recent
review of INI1 staining in CNS tumors, Judkins [20]
reported that all 68 reported cases of AT/RT’s with INI1
gene alterations have been found to lose expression of INI1
on immunohistochemistry. Additionally, the only three
reported cases of CNS tumors with loss of expression of
INI1 that were not AT/RT’s were two oligodendrogliomas
and a pituitary adenoma, which were readily differentiated
from AT/RT based on their histological appearance.
Fig. 2 Survival curves. a Kaplan–Meier curve showing overall
survival. b Kaplan–Meier curve showing survival based on extent
of resection
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The key role of INI1 in the pathogenesis of AT/RT’s has
led investigators to attempt to target this pathway. The
current paradigm of targeted therapy for cancer has focused
on the use of small molecule kinase inhibitors or mono-
clonal antibodies that inactivate pathways with gain of
function abnormalities. The fact that AT/RT’s lose the
function of INI1 makes targeted therapy in this disease a
difficult task. Recent evidence suggests, however, that the
Insulin-like growth factor 1 receptor (IGF-1R) and one of
its ligands, IGF-II, form an autocrine/paracrine loop in
AT/RT’s and that this may be crucial to tumorigenesis
[21]. Targeting the IGF-1R with antisense oligonucleotides
or a small molecule inhibitor to IGF-1R has shown efficacy
in vitro [22, 23]. Monoclonal antibodies targeting IGF-1R
are currently having some success in clinical trials for
sarcomas, while small molecule inhibitors of IGF-1R are
still being investigated [24]. This suggests that targeted
therapy for AT/RT’s may one day be possible.
One additional interesting observation from our series
was the high incidence of patients who were from twin
pregnancies (4/9 or 44%), which is significantly higher
(3/100 being the incidence of twins in California in 2005)
than expected by chance (Fisher’s exact test; P \ 0.05).
One of these patients was the product of in vitro fertiliza-
tion, which itself has been associated with infant embryo-
nal malignancies [25]. Although there is a prior report of a
twin with AT/RT [26], the small numbers involved make it
difficult to determine if an increased risk is truly associated
with multiple gestations. Future studies on AT/RT should
attempt to collect the information on presence of multiple
gestations.
In summary, young patients with AT/RT continue to
have a poor prognosis. Adding to previously published
reports, we confirm that only a small proportion of patients
with AT/RT can be cured with high dose chemotherapy
and autologous stem cell rescue. However, identifying
patients who will favorably respond to this therapy remains
difficult. Although gross total resection is clearly an
important factor in improving survival rates, the high rate
of treatment failure in the group of totally resected patients
suggests that there might be additional factors that can
modify the long-term response to chemotherapy. The
recent report from Chi et al. [9] suggests that radiation
therapy, when coupled with IRS-III based chemotherapy,
may be an important treatment strategy in this disease.
Given the small number of patients with AT/RT, a large
multi-institutional trial is needed to answer the many
therapeutic questions in this disease. Encouragingly, the
Childrens Oncology Group has recently initiated a thera-
peutic protocol specifically for AT/RT patients. This pro-
tocol provides Headstart-II based induction chemotherapy,
followed by conformal radiation, and high dose chemo-
therapy with autologous stem cell rescue. Lastly, new
agents are required for treatment of this rare but deadly
disease. Preclinical data has identified the IGF-1R pathway
as a potential target in this disease.
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